From our three decades of experience in pharma and biotechnology, we learnt to mitigate the risks associated with basic research and difficulties in monetizing such innovations.
Today our focus is on applied research that brings the Drug and Technology development to a conclusion at the earliest in an effort to commercialize those through strategic partnerships or out-licensing.

TBL's basic rules for selecting and marketing technologies

We do not undertake fundamental research such as the development of new molecules.
We consider only those technologies where the drugs of interest have already been developed to a basic degree, and proven at least to the extent of in-vitro efficacy. It is considered a bonus when the drugs have been shown positive results even in minimal animal trials.
We do not enter into retail marketing of any product on our own. For marketing, we employ a two pronged strategy:
We partner with leading companies around the world for our cutting edge technologies, either through out-licensing or other forms of collaboration.
We seek strategic alliances for our Biogenerics, to market our products either globally or regionally depending on the product and partner.

© 2011. TRANSGENE BIOTEK LIMITED., All Rights Reserved. Designed by BitraNet